Allstocks.com's Bulletin Board Post New Topic  
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Stock Picks Only » SCLL

 - UBBFriend: Email this page to someone!    
Author Topic: SCLL
Repoman75
Member


Rate Member
Icon 1 posted      Profile for Repoman75         Edit/Delete Post 
Stem Cell Innovations Produces Human Pluripotent Stem Cells
Wednesday March 29, 6:41 am ET
Cells Eligible for Use in Government Funded Laboratories


SCOTCH PLAINS, N.J.--(BUSINESS WIRE)--March 29, 2006--Dr. James H. Kelly, Chief Executive Officer of Stem Cell Innovations, Inc. (OTCBB: SCLL - News), will present data today at the Keystone Symposium on Stem Cells in Vancouver demonstrating that the Company has produced multiple lines of human pluripotent stem cells. Because these cells are derived from fetal tissue, not early embryos, they are eligible for use in laboratories funded by the National Institutes of Health.
ADVERTISEMENT


Stem cells are cells that can produce additional stem cells as well as one or more other types of cells. Pluripotent stem cells can develop into most, if not all, of the tissues of the organism. To date, two types of mammalian stem cells have been shown to be truly pluripotent: the well-known embryonic stem cells (ES cells), which are cultured from very early embryos and are patented by the University of Wisconsin, and the lesser-known embryonic germ cells (EG cells), which are developed from fetal gonadal tissue. EG cells were originally developed by Dr. Brigid Hogan and have been patented and licensed exclusively to Amphioxus Cell Technologies, Inc., a wholly owned subsidiary of the Company, but have been used in only a few laboratories because of the difficult nature of their isolation and growth. While the widespread use of ES cells has been hampered by ethical issues and government funding limitations, Congressional legislation treats fetal tissue differently. The U.S. Department of Health and Human Services has stated that research involving the derivation and use of EG cells may be conducted with Federal support (http://www.hhs.gov/ohrp/humansubjects/guidance/stemcell.pdf).

In his presentation at the Symposium, Dr. Kelly will present data demonstrating that Company scientists were able to overcome many of the problems inherent in the production of EG cells. First, the Company's cell lines are able to maintain their undifferentiated state and normal chromosome complement. Second, the Company is able to produce its cell lines without feeder layers (layers of foreign cells used as an environment to grow the stem cells which can complicate the process and result in contamination of the stem cells). Finally, the Company is able to efficiently develop multiple lines, the first step in creating banks of cells that can be matched to patients in cell therapies.

"We believe that we can make these cells efficiently and reproducibly. The Company is considering ways in which to make these cells widely available to scientists and believes that these cells can make a significant contribution to our further understanding of stem cell biology and its accelerated commercial development," Dr. Kelly said.

About Stem Cell Innovations, Inc.

Stem Cell Innovations, through its wholly owned subsidiary, Amphioxus Cell Technologies, which is based in Houston, Texas, is a cell biology company. It utilizes its proprietary C3A human liver cell line in the field of drug discovery and toxicology testing and is also engaged in the development and production of its proprietary PC(TM) pluripotent stem cells. These human cell-based disease models create a platform for the discovery, testing and development of all therapeutic modalities including small molecules, cell-based therapeutics, small interfering RNAs and antibodies.

A full copy of Dr. Kelly's presentation can be seen in the Company's Current Report on Form 8-K, filed on March 29, 2006, Exhibit 99.2 at http://www.sec.gov/cgi-bin/browse-edgar?company=&CIK=scll&filenum=&Sta te=&SIC=&owner=exclude&action=getcompany

--------------------
Stick with Repo's plan in '07 - FRPT/DKAM!

Posts: 6379 | From: PA | Registered: Dec 2004  |  IP: Logged | Report this post to a Moderator
   

Post New Topic   Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2019 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share